CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027


December 21, 2020




U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549


Re:CNS Pharmaceuticals, Inc.
  Registration Statement on Form S-1
  File No. 333-251530


Ladies and Gentlemen:


Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 P.M. (Eastern Time) on December 22, 2020, or as soon thereafter as possible on such date.


  Very truly yours,
  CNS Pharmaceuticals, Inc.

  By:  /s/ Christopher Downs
    Name: Christopher Downs
Title: Chief Financial Officer